Pharmacoepidemiology
Everything on Aqrab tagged Pharmacoepidemiology — grouped into one landing page so readers can go deeper by problem family instead of bouncing around the archive blind.
Washout Periods: When “New Use” Is Just Old Use with Better PR
A practical guide to washout periods for clinical researchers. Covers new-user definitions, refill cycles, intermittent treatment, data-history limits, and what reviewers should demand before trusting an incident-user cohort.
Exposure Lagging: When Your Induction Window Becomes Wishful Thinking
A practical guide to exposure lagging for clinical researchers. Covers induction periods, reverse causation, protopathic bias, estimand drift, and what reviewers should demand before trusting a lagged analysis.
Prevalent-User Bias: When Your Drug Study Starts After the Interesting Harm Already Happened
A practical guide to prevalent-user bias for clinical researchers. Covers depletion of susceptibles, survivor selection, post-treatment baseline covariates, and what reviewers should demand before trusting late-entry treatment cohorts.
Self-Controlled Case Series: When Each Patient Becomes Their Own Control
A practical guide to self-controlled case series for clinical researchers. Covers transient exposures, acute outcomes, fixed-confounding control, event-dependent exposure, and why within-person designs still live or die on timing assumptions.
Active Comparator New-User Design: The Observational Study Upgrade Most Drug Papers Need
A practical guide to the active comparator new-user design for clinical researchers. Covers why treated-versus-untreated comparisons fail, how new-user cohorts reduce prevalent-user bias, how active comparators narrow confounding by indication, and what reviewers should demand before trusting comparative effectiveness claims.
Explore more topics
These are ranked by how often they appear alongside Pharmacoepidemiology, so the next click is more likely to be useful than random.